Colorectal Carcinoma

Oncolytics Biotech Expands GI Tumor Scientific Advisory Board with Eileen O’Reilly, Neil Segal, and Van Morris

1 week ago talkbio0Tagged biotech, Colorectal Carcinoma, Gastrointestinal Neoplasms, GI oncology, Malignant neoplasm of anus, Neil Segal, Oncolytics, Pancreatic carcinoma, pelareorep, platform immunotherapy * *, Scientific Advisory Board, Van Morris

Oncolytics Biotech; gastrointestinal tumor; Scientific Advisory Board; Neil Segal; Van Morris; pelareorep; pancreatic cancer; colorectal cancer; anal cancer; GI oncology; platform immunotherapy

Marengo’s invikafusp alfa shows promising monotherapy activity in PD-1 resistant gastrointestinal cancers

2 months ago talkbio0Tagged Alfa, Colorectal Carcinoma, fast-track designation, High tumor mutational burden, High-Frequency Microsatellite Instability, Immunotherapy, invikafusp, Malignant neoplasm of gastrointestinal tract, Marengo Therapeutics, PDCD1 gene, resistant tumors, United States Food and Drug Administration

Invikafusp alfa; Marengo Therapeutics; PD-1 resistant tumors; Gastrointestinal cancers; Colorectal cancer; TMB-H; MSI-H; Immunotherapy; ESMO 2025; FDA Fast Track designation

Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies

2 months ago talkbio0Tagged alnodesertib, ART6043, Artios Pharma, Cancer Therapeutic Procedure, cellular response to DNA damage stimulus, Clinical Trials, Colorectal Carcinoma, DDR, investors, Malignant neoplasm of breast, Oncology Pipeline, Pancreatic carcinoma, Series D financing

Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials

Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review

3 months ago talkbio0Tagged Colorectal Carcinoma, Exelixis, kinase inhibitor [EPC], Overall Survival, regorafenib, STELLAR-303 trial, Submission, Tecentriq, Third line treatment, United States Food and Drug Administration, zanzalintinib

Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission

Roche Inks $80M Upfront Deal for Hansoh’s Cancer ADC HS-20110

3 months ago talkbio0Tagged CDH17 protein, human, Colorectal Carcinoma, Hansoh Pharmaceutical, HS-20110, milestone payments, Roche (company), royalties, Solid Neoplasm, therapeutic autologous dendritic cells, upfront payment

Roche; Hansoh Pharmaceutical; ADC; HS-20110; CDH17; colorectal cancer; solid tumors; licensing deal; upfront payment; milestone payments; royalties

Lunit AI Predicts Immunotherapy Outcomes in Colorectal, Kidney, and Lung Cancer at ESMO 2025

3 months ago talkbio0Tagged Biological Markers, Colorectal Carcinoma, Immunotherapy, Lunit AI, Malignant neoplasm of kidney, Malignant neoplasm of lung, Pathology, SCOPE IO, treatment prediction

Lunit AI; SCOPE IO; immunotherapy; colorectal cancer; kidney cancer; lung cancer; biomarkers; ESMO 2025; treatment prediction; AI pathology

Cartography Biosciences Closes $67 Million Series B Round Led by Pfizer to Advance CRC T-cell Engager

3 months ago talkbio0Tagged Antibodies, Biosciences, Cartography, CBI-1214, Cervical Atlas, Colorectal Carcinoma, Neoplasms, Pfizer Ventures, Platform, Series B funding, summit, T-Cell engager

Cartography Biosciences; Series B Funding; Pfizer Ventures; CBI-1214; T-cell engager; colorectal cancer (CRC); ATLAS platform; SUMMIT platform; antibody therapeutics; oncology

CytomX Continues Phase I ADC Study After Patient Death

5 months ago talkbio0Tagged ADC, Clinical Trials, Colorectal Carcinoma, CX-2051, CytomX, Kidney Failure, Acute, Patient Death, Phase I, Safety, therapeutic autologous dendritic cells, United States Food and Drug Administration

CytomX; CX-2051; Phase I; ADC; colorectal cancer; patient death; acute kidney injury; clinical trial; safety; FDA; trial continuation

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

7 months ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial

Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher

7 months ago talkbio0Tagged Clinical Trials, Colorectal Carcinoma, Exelixis, regorafenib, STELLAR-303, surge, Tecentriq, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge